Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on discovery, development, and commercialization of therapeutic compounds targeting the complement system. It markets two FDA-approved drugs: SYFOVRE (pegcetacoplan injection) for geographic atrophy secondary to AMD, launched March 2023, and EMPAVELI (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. For 2025, SYFOVRE generated $586.9 million and EMPAVELI $102.4 million in U.S. net product revenue.
Q2 FY2026 — expected 2026-08-22
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001193125-26-065179 | EDGAR | 122K words |
| 2025-02-28 | 2024-12-31 | 0000950170-25-029507 | EDGAR | 119K words |
| 2024-02-27 | 2023-12-31 | 0000950170-24-020614 | EDGAR | 130K words |
| 2023-02-21 | 2022-12-31 | 0000950170-23-003438 | EDGAR | 127K words |
| 2022-02-28 | 2021-12-31 | 0001564590-22-007606 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001564590-21-008800 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007350 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0001193125-25-257374 | EDGAR | 30K words |
| 2025-07-31 | 2025-06-30 | 0000950170-25-100545 | EDGAR | 28K words |
| 2025-05-07 | 2025-03-31 | 0000950170-25-064976 | EDGAR | 23K words |
| 2024-11-05 | 2024-09-30 | 0000950170-24-121062 | EDGAR | 30K words |
| 2024-08-01 | 2024-06-30 | 0000950170-24-088938 | EDGAR | 29K words |
| 2024-05-07 | 2024-03-31 | 0000950170-24-053921 | EDGAR | 24K words |
| 2023-11-01 | 2023-09-30 | 0000950170-23-057117 | EDGAR | 34K words |
| 2023-07-31 | 2023-06-30 | 0000950170-23-035935 | EDGAR | 31K words |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017819 | EDGAR | 27K words |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022606 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015500 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0000950170-22-007374 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001193125-26-134916 | EDGAR | 67K words |
| 2026-03-02 | 0001193125-26-084156 | EDGAR | 1K words |
| 2026-01-12 | 0001193125-26-010540 | EDGAR | 3K words |
| 2025-07-01 | 0001193125-25-153429 | EDGAR | 1K words |
| 2025-06-04 | 0001193125-25-134886 | EDGAR | 1K words |
| 2025-04-21 | 0001193125-25-086304 | EDGAR | 1K words |
| 2025-01-13 | 0001193125-25-005052 | EDGAR | 3K words |
| 2024-08-08 | 0001193125-24-196465 | EDGAR | 1K words |
| 2024-06-05 | 0001193125-24-155179 | EDGAR | 1K words |
| 2024-05-14 | 0001193125-24-137743 | EDGAR | 1K words |
97 total filings indexed. 68 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001492422 |
| Ticker | APLS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.apellis.com |
| Listed | 2017-11-09 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/APLS (~200 tokens, structured JSON with cryptographic provenance)